-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Currently, more than 35 million people worldwide are infected with HIV (HIV), and there are nearly 2 million new cases each year.
HIV-1 specific broad-spectrum neutralizing monoclonal antibody targeting HIV-1 envelope protein is one of the treatments under investigation for the treatment and prevention of HIV infection
One of the antibodies under investigation, named PGT121, was isolated from an African donor infected with HIV-1 subtype A.
This research comes from Beth Israel Deaconess Medical Center (BethIsrael Deaconess Medical Center)
Next, the research team evaluated antiviral activity in 13 HIV-infected people who did not receive ART therapy
After a single dose of antibody was injected, among the 9 people with a high baseline viral load, the viral load continued to decline for 7-10 days, and then rebounded to the baseline level on the 28th day
Dr.
Consistent with previous studies on anti-HIV antibody therapy, in this trial, researchers also observed that 12 of 13 subjects developed partial resistance to the antibody-HIV is rapidly responding to drug therapies and vaccine strategies The ability to develop resistance is one of the reasons the virus is so difficult to eradicate
"All in all, (this) antibody therapy is safe, well tolerated, and has a rapid antiviral effect on HIV-1 infected persons with a detectable viral load
Reference
[1] Kathryn E.
[2]'Elite neutralizing' antibody demonstrates long-term viral suppression in persons living with HIV in phase 1 trial.
